GSK Rebranded Flovent Asthma Inahler For Children To Avoid $367 Million Medicaid Rebate, Senator Hassan Accuses

Why did Trump end trade talks with Canada? How will Nike handle $1 billion tariff costs? What drove the S&P 500 to record highs? Why are big banks passing Federal Reserve stress tests? How did Meta plan to fund AI data centers? What caused Tesla’s robotaxi service issues? Why is the Supreme Court limiting nationwide injunctions?

GSK Rebranded Flovent Asthma Inahler For Children To Avoid $367 Million Medicaid Rebate, Senator Hassan Accuses

benzinga.com/markets/large-cap/25/06/46149135/gsk-rebranded-flovent-asthma-inahler-for-children-to-avoid-367-million-medicaid-rebate-senator-

U.S. Senator Maggie Hassan (D-NH) is intensifying her scrutiny of GSK Plc (NYSE:GSK) over the company's decision to pull its widely used asthma inhaler, Flovent HFA, from the market.
One year after the discontinuation, Hassan launched a formal investigation into the move, raising alarms…

This story appeared on benzinga.com, 2025-06-27 18:09:37.